HC Wainwright Has Bullish Outlook for LXEO FY2025 Earnings

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Analysts at HC Wainwright increased their FY2025 earnings per share estimates for Lexeo Therapeutics in a report issued on Tuesday, October 21st. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($2.21) per share for the year, up from their previous estimate of ($2.32). HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share. HC Wainwright also issued estimates for Lexeo Therapeutics’ Q4 2025 earnings at ($0.39) EPS, Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.34) EPS, Q3 2026 earnings at ($0.36) EPS, Q4 2026 earnings at ($0.37) EPS and FY2026 earnings at ($1.42) EPS.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.04.

Several other research firms also recently weighed in on LXEO. Oppenheimer started coverage on Lexeo Therapeutics in a research report on Thursday, July 31st. They set an “outperform” rating and a $20.00 price target for the company. Chardan Capital raised their price target on Lexeo Therapeutics from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Tuesday, October 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lexeo Therapeutics in a research report on Wednesday, October 8th. Guggenheim started coverage on Lexeo Therapeutics in a research report on Wednesday, October 15th. They set a “buy” rating and a $30.00 price target for the company. Finally, Leerink Partners raised their price target on Lexeo Therapeutics from $9.00 to $20.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Lexeo Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.57.

Lexeo Therapeutics Stock Performance

Shares of LXEO stock opened at $9.23 on Thursday. The stock has a fifty day moving average price of $6.19 and a 200 day moving average price of $4.53. The stock has a market cap of $498.42 million, a PE ratio of -2.83 and a beta of 1.66. Lexeo Therapeutics has a 1 year low of $1.45 and a 1 year high of $11.72.

Insider Activity

In related news, CEO Richard Nolan Townsend sold 13,133 shares of Lexeo Therapeutics stock in a transaction on Friday, October 17th. The stock was sold at an average price of $8.94, for a total value of $117,409.02. Following the transaction, the chief executive officer owned 242,118 shares in the company, valued at approximately $2,164,534.92. This trade represents a 5.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Tai Sandi See sold 3,888 shares of Lexeo Therapeutics stock in a transaction on Friday, October 17th. The shares were sold at an average price of $8.94, for a total value of $34,758.72. Following the completion of the transaction, the insider owned 65,862 shares in the company, valued at $588,806.28. The trade was a 5.57% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 29,091 shares of company stock valued at $232,007 over the last quarter. Company insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CWM LLC boosted its holdings in Lexeo Therapeutics by 82.2% in the third quarter. CWM LLC now owns 18,864 shares of the company’s stock valued at $125,000 after acquiring an additional 8,513 shares during the last quarter. Vestal Point Capital LP boosted its holdings in Lexeo Therapeutics by 184.1% in the second quarter. Vestal Point Capital LP now owns 3,228,161 shares of the company’s stock valued at $12,977,000 after acquiring an additional 2,091,912 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its holdings in Lexeo Therapeutics by 363.1% in the second quarter. Frazier Life Sciences Management L.P. now owns 4,424,725 shares of the company’s stock valued at $17,787,000 after acquiring an additional 3,469,210 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Lexeo Therapeutics by 20.4% during the second quarter. BNP Paribas Financial Markets now owns 48,434 shares of the company’s stock worth $195,000 after purchasing an additional 8,223 shares in the last quarter. Finally, Bridgeway Capital Management LLC lifted its stake in shares of Lexeo Therapeutics by 39.1% during the second quarter. Bridgeway Capital Management LLC now owns 53,400 shares of the company’s stock worth $215,000 after purchasing an additional 15,000 shares in the last quarter. Institutional investors and hedge funds own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.